John Flack, MD

Internist, specializing in hypertension
Internal Medicine
Accepting new patients
Call for an appointment
or

    About me

    Professional Service
    • Vice President, American Society of Hypertension (ASH) Specialist Board 2014 – present
    • Member, AHA Scientific Statement Writing Group on Resistant Hypertension 2016 – 2017
    • Member, AHA Research Strategic Outcomes Committee 2017 – present
    • Member, National Institutes of Health (NIH) Institutional Training Mechanism Review Study Section 2014 – 2018
    • Member, Psychosocial Risk and Disease Prevention Study Section, Office of Behavioral and Social sciences Diseases (NIH) 2007 – 2011
    • President, International Society on Hypertension in Blacks (ISHIB) 2001 – 2001
    • Past member, Food and Drug Administration (FDA) Cardio-renal Advisory Panel

    Editorial Boards

    • Associate Editor, American Journal of Hypertension 2016 – present
    • Associate Editor, Cardiorenal Medicine
    • Editorial Board member, Metabolic Syndrome and Drug Therapy
    • Editorial Board member, Journal of Endocrine Disorders
    • Editorial Board member, Journal of Clinical Nephrology and Research
    • Annals of Clinical and Experimental Hypertension
    • Journal of Endocrinology, Diabetes and Obesity
    • British Biotechnology Journal
    • Advances in Combination Treatments for Hypertension
    • Journal of Diabetes Research and Clinical Metabolism (JDRCM)
    • Clinical and Experimental Pharmacology and Physiology
    • Kidney and Blood Pressure Research
    • CardioRenal Medicine
    • Integrated Blood Pressure Control
    • Therapeutic Advances in Cardiovascular Disease
    • Journal of Clinical Hypertension
    • Current Cardiovascular Reports
    • Current Hypertension Reviews
    • Internal Medicine/Cardiology News

    Videos

    Remote video URL

    Gender

    Male

    Education & training

    Positions
    Professor and Chair, Department of Internal Medicine
    Chair, Population Science and Policy
    Board Certifications
    Clinical Hypertension
    Internal Medicine
    Medical School
    University of Oklahoma School of Medicine, Oklahoma City, OK
    Undergraduate Degree
    Langston University, B.S., Chemistry (Math Minor),1978
    University of Oklahoma School of Public Health, MPH, 1988
    University of Minnesota School of Public Health, MPH Epidemology, 1990
    Residency
    University of Oklahoma Health Sciences Center, Oklahoma Memorial Hospital, Oklahoma City, OK
    Chief Resident, 1985-1986
    Fellowship
    Postdoctoral Research Fellow, (Cardiovascular Epidemiology) National Heart Lung and Blood Institute, 1990
    American Society of Hypertension (FASH), Fellow - 2012

    Specialties

    Clinical locations

    Locations

    SIU Internal Medicine Clinic

    751 N. Rutledge St. Springfield, IL 62702 1st Floor
    Mon: 7:00 am-4:30 pm
    Tue: 7:00 am-7:00 pm
    Wed: 8:00 am-4:30 pm
    Thu: 7:00 am-7:00 pm
    Fri: 7:00 am-4:30 pm

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Research

    Research Interests
    Hypertension

    Clinical trials

    Trial
    Internal Medicine

    Mineralys MLS-101-301 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL ARM, MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT IN SUBJECTS WITH UNCONTROLLED AND RESISTANT HYPERTENSION

    Active recruiting

    The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.

    Eligible patients include those who currently have a diagnosis of high blood pressure, despite having taken or are currently taking anti-hypertensive medications.

    Trial
    Internal Medicine

    AstraZeneca BaxHTN: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypert

    Active recruiting

    The purpose of this clinical trial is to trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals not responding to their current treatment.

    Eligible patients include those who currently have a diagnosis of high blood pressure, despite currently taking anti-hypertensive medications.

    Trial
    Internal Medicine

    HyPhen: Title-Hypertension Phenotype Study

    Active recruiting

    This is a local research study to relate heart health and various components found in your body (body fat, sodium, etc.) to high blood pressure during pregnancy, and those with apparently normal blood pressure.

    Eligible participants include those with high blood pressure, those receiving treatment for their high blood pressure, women who had high blood pressure during pregnancy, and those with apparently normal blood pressure.

    Trial
    Internal Medicine

    Mineralys (MLS-101-202): A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL ARM, MULTI-CENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT IN SUBJECTS WITH UNCONTROLLED HYPERTENSION ON A STANDARDIZED MEDICATION REGIMEN

    Active recruiting

    The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.

    Eligible patients include those who currently have a diagnosis of high blood pressure, despite having taken or are currently taking anti-hypertensive medications.

    Trial
    Internal Medicine

    RADIANCE Continued Access Protocol (CAP): A study of the ReCor Medical Paradise System in Clinical Hypertension

    Active not recruiting
    The purpose of this clinical trial is to find out if a medical device called the Paradise Renal Denervation System can lower blood pressure in patients who have hypertension